Command Palette

Search for a command to run...

AARTIPHARM

723.74 (0.56%)

Quarterly ResultsProfit & LossBalance SheetCash Flow

Key Insights

POSITIVE
  • Net sales increased to ₹563.78 crore in Q1 2025, reflecting strong demand compared to previous quarters.
  • Operating profit and margin improved significantly to 20.62%, indicating better cost management and efficiency.
  • Net profit reached ₹88.34 crore, up by 19% from the prior quarter, demonstrating healthy growth potential.
NEGATIVE
  • Company experienced a cash flow shortfall with a 10% decrease this year [Dummy Data]
  • Company’s strategic partnerships have yet to generate expected growth. [Dummy Data]
  • Company’s EBITDA shrank at a CAGR of -8% over the past 3 years. [Dummy Data]
Quarterly Results Data
FieldTrendMar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25
Revenue
505.77555.49458.03537.78563.78386.19418.34432.27
Expenses
412.05484.03390.74442.18447.55320.54379.05371.16
Operating Profit
93.7271.4667.2995.60116.2365.6539.2961.11
Other Income
2.032.224.485.03-1.611.600.05-0.37
Interest
4.684.835.519.976.586.7910.6712.58
Depreciation
19.1220.1720.8823.0422.8222.7924.7728.62
Profit Before Tax
95.7573.6871.77100.63114.6265.4538.6962.87
Tax
30.5018.2217.1426.6426.2815.9510.7714.91
Net Profit
65.2555.4554.6273.9988.3449.5027.9247.96
EPS in Rs
7.206.126.038.169.755.463.085.29